Please Wait
Applying Filters...
menu
    • menu
    Suanfarma, at the Core of a Better Life.

    Virtual Booth

    Contact Supplier

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    Rochem, your partner in developing, sourcing, and supplying pharmaceutical & animal health ingredients of Chinese origin.

    Virtual Booth

    Contact Supplier

    Transo-Pharm GmbH works globally to supply Active Pharmaceutical Ingredients adhering to the highest quality & GMP standards.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2025-01-20

    Virtual Booth

    Contact Supplier

    Menu

    Savolitinib

    DEVELOPMENTS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Hutchmed's Priority Review For Orpathys-Tagrisso In Lung Cancer
    Hutchmed's Priority Review For Orpathys-Tagrisso In Lung Cancer

    01 Jan 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/01/02/3003295/0/en/HUTCHMED-Announces-NDA-Acceptance-in-China-with-Priority-Review-Status-for-ORPATHYS-and-TAGRISSO-Combination-in-Lung-Cancer-Patients-with-MET-amplification-After-Progression-on-Fir.html

    GLOBENEWSWIRE
    01 Jan 2025
    Share Share
    Hutchmed Announces Breakthrough Designation for Orpathys & Tagrisso
    Hutchmed Announces Breakthrough Designation for Orpathys & Tagrisso

    11 Dec 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/12/12/2995863/0/en/HUTCHMED-Announces-Breakthrough-Therapy-Designation-in-China-for-ORPATHYS-and-TAGRISSO-Combination-in-Certain-Lung-Cancer-Patients-After-Disease-Progression-on-EGFR-Inhibitor-Thera.html

    GLOBENEWSWIRE
    11 Dec 2024
    Share Share
    Hutchmed's ORPATHYS® Maintains Inclusion In China’s NDL
    Hutchmed's ORPATHYS® Maintains Inclusion In China’s NDL

    28 Nov 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/11/28/2988577/0/en/HUTCHMED-Announces-Continued-Inclusion-of-ORPATHYS-savolitinib-in-the-National-Reimbursement-Drug-List-in-China-at-Current-Terms.html

    GLOBENEWSWIRE
    28 Nov 2024
    Share Share
    HUTCHMED Tagrisso Plus Orpathys High Response In Lung Cancer
    HUTCHMED Tagrisso Plus Orpathys High Response In Lung Cancer

    16 Oct 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/10/16/2963756/0/en/HUTCHMED-Announces-that-TAGRISSO-plus-ORPATHYS-demonstrated-high-clinically-meaningful-response-rate-in-lung-cancer-patients-with-high-levels-of-MET-overexpression-and-or-amplifica.html

    GLOBENEWSWIRE
    16 Oct 2024
    Share Share
    HUTCHMED To Present Clinical Data At ESMO And World Lung Cancer Conf
    HUTCHMED To Present Clinical Data At ESMO And World Lung Cancer Conf

    08 Sep 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/09/09/2942477/0/en/HUTCHMED-Highlights-Clinical-Data-to-be-Presented-at-ESMO-Congress-2024-and-the-2024-World-Conference-of-Lung-Cancer.html

    GLOBENEWSWIRE
    08 Sep 2024
    Share Share
    China NMPA accepts for review Hutchmed’s sNDA for savolitinib
    China NMPA accepts for review Hutchmed’s sNDA for savolitinib

    29 Mar 2024

    // PHARMABIZ

    https://www.pharmabiz.com/NewsDetails.aspx?aid=168216&sid=2

    PHARMABIZ
    29 Mar 2024
    Share Share